<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68743">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01818440</url>
  </required_header>
  <id_info>
    <org_study_id>130092</org_study_id>
    <secondary_id>13-CC-0092</secondary_id>
    <nct_id>NCT01818440</nct_id>
  </id_info>
  <brief_title>Fluoroscopy or 3-D Roadmap Imaging Software for Liver Tumor Treatment</brief_title>
  <official_title>Prospective Randomized Multicenter Trial Comparing Navigation With 3D Roadmap vs. Conventional Angiography During Transarterial Embolization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Researchers are interested in comparing two methods that doctors can use to position
      catheters in blood vessels. These methods are used to deliver chemotherapy and close the
      blood supply to a tumor. The methods are the standard method called fluoroscopy and a new
      way called    3-D Roadmap.    The 3-D Roadmap software uses computed tomography (CT) images
      to help the doctor choose the best position for the catheter to get to the tumor. The
      computer shows the route on an x-ray screen in real time. This technique may help doctors
      position the catheter with less x-ray dye and in a shorter time. These methods will be
      compared in people who are having a procedure to destroy liver tumors. The procedure, called
      trans-arterial embolization, will deliver chemotherapy and destroy the tumor blood supply.

      Objectives:

      - To compare the effectiveness of fluoroscopy or 3-D Roadmap software for liver tumor
      treatment.

      Eligibility:

      - Individuals at least 18 years of age who are having trans-arterial embolization for liver
      cancer.

      Design:

        -  Participants will be screened with a physical exam and medical history. They will
           provide blood and urine samples, and have imaging studies.

        -  Participants will be divided into two groups. One group will have regular fluoroscopy
           (X-ray) during the procedure. The other group will have the procedure with the 3-D
           Roadmap software.

        -  In the first group, participants will have a CT scan. The doctor will decide how many
           vessels need to be treated. The doctor will advance the catheter using fluoroscopy
           only. Another CT scan will be given after the procedure.

        -  In the second group, participants will have a CT scan. The doctor will look at the scan
           with the 3-D Roadmap software. The software will show the path to advance the catheter.
           The doctor will use the software to help destroy the tumors. Another CT scan will be
           given after the procedure.

        -  Both groups will have the same follow-up care afterward. Other tests will be given as
           needed for the cancer treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      This is a phase II prospective randomized trial comparing novel tumor segmentation and
      navigation with 3D roadmap vs. conventional imaging with angiography during trans-arterial
      embolization procedures. Cone beam CT (CBCT) obtains CT-like images in the angiography suite
      during trans-arterial chemoembolization procedures and liver chemo-perfusion (PHP). In
      addition, 2D liver perfusion metrics can be calculated from angiography images. 3D Roadmap
      is a navigation tool that utilizes the data from the CBCT overlaid on live fluoroscopy to
      display a segmented tumor, delineate its vascular supply and to navigate catheters to the
      target vessels. Moreover, with 3D Roadmap, CBCT can be fused to prior CT or MRI for improved
      target visualization.

      Primary Objective:

      To compare safety, and technical efficiency of navigation with 3D Roadmap vs. conventional
      image guidance during trans-arterial embolization procedures.

      Eligibility:

      Subjects are eligible if:

        -  They are more than 18 years of age

        -  They have primary or metastatic hepatic tumors scheduled for trans-arterial chemo-
           embolization or bland embolization in interventional radiology

        -  They are eligible for trans-arterial chemoembolization or bland embolization

      Subjects are excluded if they have:

        -  An altered mental status precluding understanding or consenting for the procedure

        -  Contra-indications to trans-arterial embolization

        -  A gross body weight exceeding 375 pounds (upper limit of angio table)

        -  A pregnancy

        -  A severe allergic reaction to iodine contrast which cannot be controlled by
           premedication with antihistamines and steroids

      Design:

        -  Number of Participants: 30

        -  Recruitment Time Frame: 2 years

        -  Number of sites: 2

        -  Type of Study: prospective randomized clinical trial
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To compare safety, efficacy, and technical efficiency of navigation with 3D Roadmap vs. conventional image guidance during trans-arterial embolization procedures.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the clinical utility and image quality of 2D perfusion software images compare to standard angiography images.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Image-Guided Surgery</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3D Roadmap software</intervention_name>
    <description>N/A</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Patients must have primary or metastatic hepatic tumors scheduled for
                  trans-arterial chemo-embolization or bland embolization in interventional
                  radiology. A multidisciplinary team including oncology, surgery, pathology and
                  radiation oncology as well as interventional radiology will review each
                  candidate and determine the eligibility for TACE or bland embolization and
                  ineligibility for other interventions.

               2. Age &gt; 18 years

               3. They must be eligible for trans-arterial chemoembolization or bland embolization

        EXCLUSION CRITERIA:

          1. Patients with an altered mental status precluding understanding or consenting for the
             procedure

          2. History of allergic reactions to iodine contrast, which cannot be controlled by
             premedication with antihistamines and steroids.

          3. Pregnant women are excluded from the study because ionizing radiation is teratogenic
             or abortifacient effects.

          4. Patients with a total body weight exceeding 375 pounds since that is the weight limit
             of the angiography table.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine Abi-Jaoudeh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health Clinical Center (CC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charisse Garcia, R.N.</last_name>
    <phone>(301) 594-4511</phone>
    <email>garciacr@mail.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadine Abi-Jaoudeh, M.D.</last_name>
    <phone>(301) 402-1386</phone>
    <email>abijaoudehn@mail.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@mail.cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2013-CC-0092.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Meyer BC, Witschel M, Frericks BB, Voges M, Hopfenm√ºller W, Wolf KJ, Wacker FK. The value of combined soft-tissue and vessel visualisation before transarterial chemoembolisation of the liver using C-arm computed tomography. Eur Radiol. 2009 Sep;19(9):2302-9. doi: 10.1007/s00330-009-1410-x. Epub 2009 May 8.</citation>
    <PMID>19424701</PMID>
  </reference>
  <reference>
    <citation>Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res. 2007 Feb 1;67(3):1030-7.</citation>
    <PMID>17283135</PMID>
  </reference>
  <reference>
    <citation>Wallace MJ, Murthy R, Kamat PP, Moore T, Rao SH, Ensor J, Gupta S, Ahrar K, Madoff DC, McRae SE, Hicks ME. Impact of C-arm CT on hepatic arterial interventions for hepatic malignancies. J Vasc Interv Radiol. 2007 Dec;18(12):1500-7.</citation>
    <PMID>18057284</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>March 14, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgical Navigation</keyword>
  <keyword>Liver</keyword>
  <keyword>Cancer</keyword>
  <keyword>Image-guided Therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
